Peptides and Heparin Market Research: Global Status & Forecast by Geography, Type & Application (2015-2025)
Region:Global
Product Code:99SGL228Lif20190500008301
May 2019
62
About the Report
According to 99Strategy, the Global Peptides and Heparin Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during the 2020-2025. The report analyses the global Peptides and Heparin market, the market size and growth, as well as the major market participants.
The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.
Key Regions
Asia Pacific
North America
Europe
South America
Middle East & Africa
Key Companies
Cipla Ltd.
Emcure Pharmaceuticals Pvt. Ltd.
Gland Pharma Limited
Troikaa Pharmaceuticals Ltd.
Biological E Limited
Bharat Biotech
Samarth Life Sciences Pvt. Ltd.
VHB Life Sciences Limited
Celon Laboratories Pvt. Ltd.
United Biotech (P) Limited
Biocon Limited
Sun Pharmaceutical Industries Ltd.
Wockhardt Ltd.
Key Product Type
Insulin
Teriparatide
Liraglutide
Leuprolide
Leuprolide
Exenatide
Calcitonin
Enaxaparin Sodium
Heparin Sodium
Market by Application
Diabetes
Infectious Diseases
Cancer
Osteoporosis
Main Aspects covered in the Report
Overview of the Peptides and Heparin market including production, consumption, status & forecast and market growth
2015-2018 historical data and 2019-2025 market forecast
Geographical analysis including major countries
Overview the product type market including development
Overview the end-user market including development
Scope of the Report
Products
Table of Contents
Table of Content
1 Industrial Chain Overview
1.1 Peptides and Heparin Industry
1.1.1 Overview
1.1.2 Characteristics of Peptides and Heparin
1.2 Upstream
1.2.1 Major Materials
1.2.2 Manufacturing Overview
1.3 Product List By Type
1.3.1 Insulin
1.3.2 Teriparatide
1.3.3 Liraglutide
1.3.4 Leuprolide
1.3.5 Leuprolide
1.3.6 Exenatide
1.3.7 Calcitonin
1.3.8 Enaxaparin Sodium
1.3.9 Heparin Sodium
1.4 End-Use List
1.4.1 Demand in Diabetes
1.4.2 Demand in Infectious Diseases
1.4.3 Demand in Cancer
1.4.4 Demand in Osteoporosis
1.5 Global Market Overview
1.5.1 Global Market Size and Forecast, 2015-2025
1.5.2 Global Market Size and Forecast by Geography with CAGR, 2015-2025
1.5.3 Global Market Size and Forecast by Product Type with CAGR, 2015-2025
1.5.4 Global Market Size and Forecast by End-Use with CAGR, 2015-2025
2 Global Production & Consumption by Geography
2.1 Global Production & Consumption
2.1.1 Global Production
2.1.2 Global Consumption
2.2 Geographic Production & Consumption
2.2.1 Production
2.2.1.1 Asia-Pacific
2.2.1.2 North America
2.2.1.3 South America
2.2.1.4 Europe
2.2.1.5 Middle East & Africa
2.2.2 Consumption
2.2.2.1 Asia-Pacific
2.2.2.2 North America
2.2.2.3 South America
2.2.2.4 Europe
2.2.2.5 Middle East & Africa
3 Major Manufacturers Introduction
3.1 Manufacturers Overview
3.2 Manufacturers List
3.2.1 Cipla Ltd. Overview
3.2.1.1 Product Specifications
3.2.1.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.1.3 Recent Developments
3.2.1.4 Future Strategic Planning
3.2.2 Emcure Pharmaceuticals Pvt. Ltd. Overview
3.2.2.1 Product Specifications
3.2.2.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.2.3 Recent Developments
3.2.2.4 Future Strategic Planning
3.2.3 Gland Pharma Limited Overview
3.2.3.1 Product Specifications
3.2.3.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.3.3 Recent Developments
3.2.3.4 Future Strategic Planning
3.2.4 Troikaa Pharmaceuticals Ltd. Overview
3.2.4.1 Product Specifications
3.2.4.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.4.3 Recent Developments
3.2.4.4 Future Strategic Planning
3.2.5 Biological E Limited Overview
3.2.5.1 Product Specifications
3.2.5.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.5.3 Recent Developments
3.2.5.4 Future Strategic Planning
3.2.6 Bharat Biotech Overview
3.2.6.1 Product Specifications
3.2.6.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.6.3 Recent Developments
3.2.6.4 Future Strategic Planning
3.2.7 Samarth Life Sciences Pvt. Ltd. Overview
3.2.7.1 Product Specifications
3.2.7.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.7.3 Recent Developments
3.2.7.4 Future Strategic Planning
3.2.8 VHB Life Sciences Limited Overview
3.2.8.1 Product Specifications
3.2.8.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.8.3 Recent Developments
3.2.8.4 Future Strategic Planning
3.2.9 Celon Laboratories Pvt. Ltd. Overview
3.2.9.1 Product Specifications
3.2.9.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.9.3 Recent Developments
3.2.9.4 Future Strategic Planning
3.2.10 United Biotech (P) Limited Overview
3.2.10.1 Product Specifications
3.2.10.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.10.3 Recent Developments
3.2.10.4 Future Strategic Planning
3.2.11 Biocon Limited Overview
3.2.11.1 Product Specifications
3.2.11.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.11.3 Recent Developments
3.2.11.4 Future Strategic Planning
3.2.12 Sun Pharmaceutical Industries Ltd. Overview
3.2.12.1 Product Specifications
3.2.12.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.12.3 Recent Developments
3.2.12.4 Future Strategic Planning
3.2.13 Wockhardt Ltd. Overview
3.2.13.1 Product Specifications
3.2.13.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.13.3 Recent Developments
3.2.13.4 Future Strategic Planning
4 Market Competition Pattern
4.1 Market Size and Sketch
4.2 Company Market Share
4.2.1 Global Production by Major Manufacturers
4.2.2 Market Concentration Analysis
4.3 Market News and Trend
4.3.1 Merger & Acquisition
4.3.2 New Product Launch
5 Product Type Segment
5.1 Global Overview by Product Type Segment
5.2 Segment Subdivision by Product Type
5.2.1 Market in Insulin
5.2.1.1 Market Size
5.2.1.2 Situation & Development
5.2.2 Market in Teriparatide
5.2.2.1 Market Size
5.2.2.2 Situation & Development
5.2.3 Market in Liraglutide
5.2.3.1 Market Size
5.2.3.2 Situation & Development
5.2.4 Market in Leuprolide
5.2.4.1 Market Size
5.2.4.2 Situation & Development
5.2.5 Market in Leuprolide
5.2.5.1 Market Size
5.2.5.2 Situation & Development
5.2.6 Market in Exenatide
5.2.6.1 Market Size
5.2.6.2 Situation & Development
5.2.7 Market in Calcitonin
5.2.7.1 Market Size
5.2.7.2 Situation & Development
5.2.8 Market in Enaxaparin Sodium
5.2.8.1 Market Size
5.2.8.2 Situation & Development
5.2.9 Market in Heparin Sodium
5.2.9.1 Market Size
5.2.9.2 Situation & Development
6 End-Use Segment
6.1 Global Overview by End-Use Segment
6.2 Segment Subdivision
6.2.1 Market in Diabetes
6.2.1.1 Market Size
6.2.1.2 Situation & Development
6.2.2 Market in Infectious Diseases
6.2.2.1 Market Size
6.2.2.2 Situation & Development
6.2.3 Market in Cancer
6.2.3.1 Market Size
6.2.3.2 Situation & Development
6.2.4 Market in Osteoporosis
6.2.4.1 Market Size
6.2.4.2 Situation & Development
7 Market Forecast & Trend
7.1 Regional Forecast
7.2 Consumption Forecast
7.2.1 Product Type Forecast
7.2.2 End-Use Forecast
7.3 Investment Trend
7.4 Consumption Trend
8 Price & Channel
8.1 Price and Cost
8.1.1 Price
8.1.2 Cost
8.2 Channel Segment
9 Market Drivers & Investment Environment
9.1 Market Drivers
9.2 Investment Environment
10 Research Conclusion
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.